Ascendis Pharma A/S
ASND173.500USD
+6.720+4.03%
Close 07/31, 16:00（ET）Quotes delayed by 15 min
10.58BMarket Cap
LossP/E TTM
More Details of Ascendis Pharma A/S Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
Ticker SymbolASND
Company nameAscendis Pharma A/S
IPO dateJan 28, 2015
Founded at2006
CEOMr. Jan Moller Mikkelsen
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJan 28
AddressTuborg Boulevard 12
CityHELLERUP
Stock exchangeNASDAQ Global Select Consolidated
CountryDenmark
Postal code2900
Phone4570222244
Websitehttps://ascendispharma.dk/
Ticker SymbolASND
IPO dateJan 28, 2015
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Revenue Breakdown
Currency: EURUpdated: Sun, Jul 6
Currency: EURUpdated: Sun, Jul 6
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessEUR
Name
Revenue
Proportion
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
By RegionEUR
Name
Revenue
Proportion
North America
73.69M
72.99%
Europe
21.33M
21.13%
Rest of world
5.94M
5.88%
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Commercial sale of products
96.03M
95.12%
Rendering of services
3.52M
3.49%
License
1.40M
1.39%
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
17.03%
Westfield Capital Management Company, L.P.
9.08%
Avoro Capital Advisors LLC
8.64%
Janus Henderson Investors
7.43%
Fidelity Management & Research Company LLC
7.13%
Other
50.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
41.95%
Investment Advisor
39.67%
Venture Capital
17.38%
Hedge Fund
8.82%
Research Firm
4.70%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Pension Fund
0.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
499
70.49M
116.76%
-1.46M
2025Q1
513
68.89M
114.10%
-3.55M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.28M
17.03%
+168.75K
+1.67%
Mar 31, 2025
Westfield Capital Management Company, L.P.
5.48M
9.08%
-48.98K
-0.89%
Mar 31, 2025
Avoro Capital Advisors LLC
5.22M
8.64%
+114.94K
+2.25%
Mar 31, 2025
Janus Henderson Investors
4.49M
7.43%
+106.57K
+2.43%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.30M
7.13%
-52.57K
-1.21%
Mar 31, 2025
Artisan Partners Limited Partnership
4.26M
7.05%
-193.79K
-4.35%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.05M
5.06%
+328.28K
+12.04%
Mar 31, 2025
Capital International Investors
2.87M
4.76%
+11.54K
+0.40%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.26M
3.74%
-27.11K
-1.19%
Mar 31, 2025
MFS Investment Management
1.87M
3.1%
+9.63K
+0.52%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Harbor Health Care ETF
18.34%
AdvisorShares Dorsey Wright ADR ETF
2.58%
American Century Focused Dynamic Growth ETF
2.27%
BNY Mellon Innovators ETF
2.26%
Virtus LifeSci Biotech Products ETF
2.01%
Tema Heart & Health ETF
1.25%
ProShares Ultra Nasdaq Biotechnology
1.19%
Invesco Nasdaq Biotechnology ETF
1.11%
Main Thematic Innovation ETF
0.76%
Putnam Sustainable Future ETF
0.75%
View more
Harbor Health Care ETF
Proportion18.34%
AdvisorShares Dorsey Wright ADR ETF
Proportion2.58%
American Century Focused Dynamic Growth ETF
Proportion2.27%
BNY Mellon Innovators ETF
Proportion2.26%
Virtus LifeSci Biotech Products ETF
Proportion2.01%
Tema Heart & Health ETF
Proportion1.25%
ProShares Ultra Nasdaq Biotechnology
Proportion1.19%
Invesco Nasdaq Biotechnology ETF
Proportion1.11%
Main Thematic Innovation ETF
Proportion0.76%
Putnam Sustainable Future ETF
Proportion0.75%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
